EBV gp350, also known as Epstein-Barr virus glycoprotein 350, plays a crucial role in the virus's ability to infect host cells. As the most abundant glycoprotein on the surface of the EBV viral envelope, gp350 is primarily responsible for binding to the CD21 receptor on B cells, facilitating viral entry. Understanding the structure and function of EBV gp350 is essential for developing effective vaccines and therapeutic strategies against Epstein-Barr virus-related diseases, including infectious mononucleosis and certain types of cancer. Researchers are actively exploring how targeting EBV gp350 can enhance immune responses, potentially leading to breakthroughs in preventing and treating EBV infections.